Resistance to Antiviral Drugs: The End of Innocence

New England Journal of Medicine

Volumn 320, Issue 5, 1989, Pages 313-314

  Hirsch, Martin S ^a   Schooley, Robert T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR; THYMIDINE KINASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CYTOMEGALOVIRUS INFECTION; DRUG RESISTANCE; EDITORIAL; HERPES VIRUS INFECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL;

EID: 0024579619     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198902023200510     Document Type: Editorial

References (17)

1. Erlich KS, Mills J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989; 320: 293–6.
2. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH Jr, Jordan MC. Progressive disease due to ganciclovir-resistant cytomegalovirus in immuno-compromised patients. N Engl J Med 1989; 320: 289–93.
3. Schinazi RF, del Bene V, Scott RT, Dudley-Thorpe J-B. Characterization of acyclovir-resistant and -sensitive herpes simplex viruses isolated from a patient with an acquired immune deficiency. J Antimicrob Chemother 1986; 18: Suppl B: 127–34.
4. Norris SA, Kessler HA, Fife KH. Severe, progressive herpetic whitlow caused by an acyclovir-resistant virus in a patient with AIDS. J Infect Dis 1988; 157: 209–10.
5. Ellis MN, Keller PM, Fyfe JA, et al. Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity. Antimicrob Agents Chemother 1987; 31: 1117–25.
6. Parker achéal, Craig JIO, Collins P, Oliver N, Smith J. Acyclovir-resistant herpes simplex virus infection due to altered DNA polymerase. Lancet 1987; 2: 1461.
7. Field HJ, Coen DM. Pathogenicity of herpes simplex virus mutants containing drug resistant mutations in the viral DNA polymerase gene. J Virol 1986; 60: 286–9.
8. Field HJ, Darby G. Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo. Antimicrob Agents Chemother 1980; 17: 209–16.
9. Chatis PA, Miller CH, Schrager LE, Crumpacker CS. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N Engl J Med 1989; 320: 297–300.
10. Walmsley SL, Chew E, Read SE, et al. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet). J Infect Dis 1988; 157: 569–72.
11. Youle MM, Hawkins DA, Collins P, et al. Acyclovir-resistant herpes in AIDS treated with foscarnet. Lancet 1988; 2: 341–2.
12. De Clercq E, Holy A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986; 323: 464–7.
13. Ambinder RF, Burns WH, Leitman PS, Saral R. Prophylaxis: a strategy to minimise antiviral resistance. Lancet 1984; 1: 1154–5.
14. Gold D, Corey L. Acyclovir prophylaxis for herpes simplex virus infection. Antimicrob Agents Chemother 1987; 31: 361–7.
15. Parris DS, Harrington JE. Herpes simplex virus variants resistant to high concentrations of acyclovir exist in clinical isolates. Antimicrob Agents Chemother 1982; 22: 71–7.
16. Straus SE, Takiff HE, Seidlin M, et al. Suppression of frequently recurring genital herpes: a placebo-controlled double-blind trial of oral acyclovir. N Engl J Med 1984; 310: 1545–50.
17. Nusinoff Lehrman S, Douglas JW, Corey L, Barry DW. Recurrent genital herpes and suppressive oral acyclovir therapy: relationship between clinical outcome and in-vitro drug sensitivity. Ann Intern Med 1986; 104: 786–90.